Second Heart Assist Completes Successful South American HRPCI Study with Whisper™ Device

Second Heart Assist Completes Successful HRPCI Study



Second Heart Assist Inc., based in Utah, has announced the completion of an extensive clinical trial in Paraguay that spotlighted its innovative device, the Whisper™, designed for mechanical circulatory support (MCS) during high-risk percutaneous coronary intervention (HRPCI). This third study has yielded encouraging results, affirming the Whisper's capability to enhance patient outcomes significantly.

The trial was conducted at the Sanatorio Italiano Hospital in Asuncion, where Dr. Adrian Ebner and his clinical team closely monitored outcomes involving 20 patients undergoing PCI procedures. The Whisper™ device has consistently showcased its safety and efficacy across various studies, and the latest findings further solidify its position as a leading option in medical technology.

One primary conclusion of the study is the significant improvement in systemic blood flow attributed to the Whisper™. This device is strategically positioned in the abdominal aorta, allowing it to boost both systemic and renal blood flow effectively. Notably, this advancement enables enhanced perfusion benefits, particularly in addressing the harmful effects of contrast dye used during PCI procedures. Remarkably, the study noted an increase in urine output that surpassed competing devices, achieving results between four to ten times higher than baseline measurements.

Dr. Ebner expressed admiration for the Whisper's performance, stating, "The perfusion efficiency exhibited in these cases is remarkable. It is not only safe and easy to deploy, but its quick utilization is truly impressive." The deployment process for the Whisper™ took, on average, less than a minute, while removal was completed in under 30 seconds, reinforcing its reputation as one of the most user-friendly MCS devices on the market.

Alex Richardson, Chief Technology Officer at Second Heart Assist, emphasized the importance of efficiency in clinical settings. He remarked, "The ability for clinicians to utilize our device quickly and safely has been a crucial factor in its performance, attracting positive attention from industry leaders."

Throughout the trials, every patient using the Whisper™ noted improvements in cardiac output with stable hemodynamics and minimal hemolysis. Jeffrey Donofrio, CEO of Second Heart Assist, reflected on the significance of the study, asserting that, after three decades in heart failure device innovation, the company is making strides in enhancing mechanical circulatory support options for HRPCI and advanced heart failure.

As Dr. Leslie Miller, Chief Medical Officer, highlighted, this study aligns with the company's mission to address the unmet needs in heart failure and kidney support without invasive surgical procedures. The design of the Whisper™, aimed at offering both cardiac and renal protection, underlines its potential to effectively address significant healthcare challenges.

The findings and the continual advancements in Second Heart Assist’s technology herald a promising future for the Whisper™ device. With unique attributes and a focus on easy and reliable application, the company anticipates gaining a substantial share in the market, answering calls for improved solutions in heart failure treatment and supportive care. As the Whisper™ gains traction, it may redefine traditional approaches, paving the way for safer and more dependable patient care in cardiology and beyond.

In conclusion, Second Heart Assist is committed to revolutionizing the landscape of mechanical circulatory support, ensuring that both patients and healthcare providers benefit from their innovations. The Whisper™ device stands as a testament to the successful merging of technology and clinical efficacy in advancing heart failure treatment protocols.

Topics Health)

【About Using Articles】

You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.

【About Links】

Links are free to use.